Canberra: COVID-19 vaccine developed by Novavax, was authorised for use in Australia on Thursday. For its 26 million people, the country has bought 51 million doses of the vaccine under brand name “Nuvaxovid”, which is manufactured in the United States. Vaccines from Pfizer, AstraZeneca, and Moderna are already in use in Australia. The Janssen vaccine from Johnson & Johnson has also been approved, but the government has yet to purchase any.
The Novavax vaccine will be offered to unvaccinated Australians aged 18 and up, but not as a booster for the 95 percent of the population aged 16 and up who have already been vaccinated.
Despite the high rate of immunisation in the United States, some people have been waiting for Novavax, and it's excellent that it's now been licenced, according to chief regulator John Skerritt of the Therapeutic Goods Administration. Our dream is to turn our 95 percent in this country into a 97 or 98 percent,' Skerritt remarked.The protein-based vaccination will be given in two doses separated by three weeks.
Australia, according to Paul Griffin, an associate professor of medicine at Queensland University, must seek to improve on its already remarkable immunisation rate.